Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01208935|
Recruitment Status : Completed
First Posted : September 24, 2010
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Tobacco Dependence||Drug: Nicotine Patch Drug: Nicotine Gum||Phase 2 Phase 3|
We hypothesize that two nicotine replacement delivery systems (patch and gum) are both safe and efficacious for the treatment of adolescent nicotine dependence. Consequently, use of both the patch and gum should be tolerable in this population with only minor adverse side-effects. Secondly, some individuals in both groups (patch, gum) may benefit from either cessation or reduction in smoke exposure, as a result of the distinctly different mechanisms of the two treatments (steady state vs. intermittent delivery of NRT).
A.The primary objectives of this study are:
- to evaluate the comparative safety of the nicotine transdermal system (21 mg "patch") and the nicotine gum (2 mg and 4 mg), dosed appropriately to pre-treatment levels of smoking, to initiate and sustain smoking cessation and reduction ;
- to compare compliance levels with the patch and gum;
- to evaluate the comparative efficacy of the patch and the gum to initiate and sustain smoking cessation and reduction;
- to compare the rates of biochemically-verified continuous abstinence by using intent-to-treat analysis based on individual subject outcome.
B.The secondary objectives of this study are:
- to correlate pre-treatment nicotine exposure (saliva cotinine) with withdrawal intensity measured in all groups during treatment and with treatment outcome;
- to compare biological markers of smoke exposure (expired air CO and saliva thiocyanate) with self-reports of smoking and to correlate them with withdrawal symptomatology and treatment outcome;
- to obtain smoking topography data (puff volume, velocity of intake, interpuff interval, and puffs per cigarette) on adolescent patterns of smoking as an index of smoking intensity and exposure and to correlate pre-treatment smoking intensity with treatment outcome.
C.The tertiary objectives are:
- to examine the validity of the use of biochemical markers of smoke exposure (expired air CO and saliva thiocyanate) as potential markers of smoking cessation in adolescents;
- to compare the relative cotinine exposure of adolescents who are smoking with those who are receiving nicotine replacement who do and do not successfully quit
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||157 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence|
|Study Start Date :||August 1999|
|Primary Completion Date :||June 2004|
|Study Completion Date :||August 2004|
- a)Safety will be tabulated as a function of reported and observed adverse side-effects.
- b)Tolerability and Compliance by attendance at visits, completeness of smoking cessation diaries, saliva cotinine, and correlations of biologic markers (expired air CO and saliva thiocyanate) with smoking cessation diaries.
- c) Efficacy by Minnesota Withdrawal scale, craving visual analog scales and Questionnaire of Smoking Urges, smoking abstinence/reduction (as per self-reported data in smoking cessation diaries), expired air CO and saliva thiocyanate.
- d) Weight and body mass index (BMI)
- e)Cognitive performance tests
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01208935
|United States, Maryland|
|Teen Tobacco Addiction Research Clinic|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||Eric T. Moolchan, M.D.||National Institutes on Drug Abuse IRP/ NIH|